Drugs / Follicle Stimulating Hormone Receptor T Cells
Follicle Stimulating Hormone Receptor T Cells
also known as
FSHCER T cells
Cell therapy targets FSHR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05316129 | Apr 2022 → Jul 2026 overdue | ovarian cancer | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Follicle Stimulating Hormone Receptor T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05316129 ↗ |
| Known as | FSHCER T cells | “The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor)...” NCT05316129 ↗ |
| Modality | Cell therapy | “Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.” NCT05316129 ↗ |
| Target | FSHR | “targeting the FSHR (follicle-stimulating hormone receptor)” NCT05316129 ↗ |